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Abstract
Delayed graft function (DGF) is very high in our center (70%- 80%), and we usually 
receive a kidney for transplant after more than 22 hours of static cold ischemia time 
(CIT). Also, there is an inadequate care of the donors, contributing to a high rate of 
DGF. We decided to test whether machine perfusion (MP) after a CIT improved the 
outcome of our transplant patients. We analyzed the incidence of DGF, its duration, 
and the length of hospital stay (LOS) in patients who received a kidney preserved with 
MP after a CIT (hybrid perfusion—HP). We included 54 deceased donors kidneys pre-
served with HP transplanted from Feb/13 to Jul/14, and compared them to 101 kid-
ney transplants preserved by static cold storage (CS) from Nov/08 to May/12. The 
median pumping time was 11 hours. DGF incidence was 61.1% vs 79.2% (P = .02), 
median DGF duration was 5 vs 11 days (P < .001), and median LOS was 13 vs 18 days 
(P < .011), for the HP compared to CS group. The observed reduction of DGF with 
machine perfusion did not occur in donors over 50 years old. In the multivariate analy-
sis, risk factors for DGF, adjusted for CIT, were donor age (OR, 1.04; P = .005) and the 
absence of use of MP (OR, 1.54; P = .051). In conclusion, the use of HP contributed to 
faster recovery of renal function and to a shorter length of hospital stay.
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1  | INTRODUCTION
Delayed graft function (DGF) is an important prognostic factor after 
transplantation. It is associated with high rates of complications, 
such as rejection and infections; poorer long- term graft survival; lon-
ger hospitalization; and higher costs.1,2 In Brazil, 50%- 80% of renal 
transplants from deceased donors evolve with DGF,2-6 compared 
with low rates reported in transplantation centers of the United 
States7 and Europe.8 This problem in Brazil is mainly due to long cold 
ischemia time (CIT), generally longer than 20 hours, and inadequate 
maintenance of donors after brain death diagnosis.2,4,6 The mainte-
nance of the donor after brain death diagnosis is not often possi-
ble in public intensive care units, which are often crowded and lack 
skilled professionals and/or dedicated staff to care for donors.4,9,10 
In addition, following a worldwide trend, the use of donors with ex-
panded criteria (UNOS ECD system criteria) is increasing; such use 
currently constitutes 20%- 30% of donors in Brazil and might con-
tribute for the increase of DGF rate.3,6,7,11
In Brazil, long CIT depends on the logistics of donation and allo-
cation of organs.4 To reduce the CIT, it is necessary to optimize the 
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laboratory compatibility testing, the allocation of recipients, and their 
early arrival at transplant center.4
Studies have shown that the use of machine perfusion (MP) 
provided better results than static cold storage (CS) preservation 
method in such outcomes as reduced risk for DGF and better graft 
survival in the first and third years after transplantation. These find-
ings were observed in both standard donor organs and organs from 
donors with expanded criteria.8,10,12
Our institution is located in the state of São Paulo, where 36% of 
deceased donors kidney transplantations in 2014 were performed in 
Brazil.13 Donation after cardiac death has not been accepted in Brazil. 
In São Paulo, the process of procurement and allocation begins after 
the State Coordination of São Paulo is notified of a potential brain- 
dead donor; this Coordination is responsible for the control of patients 
on the waiting list and allocation of organs. After notification, State 
Coordination contacts the organ procurement organization (OPO) 
that acts in the region where the hospital of the donor is located. The 
OPO is responsible to support all organ procurement processes, clin-
ical evaluation of the donor with confirmation of brain death diagno-
sis, viability assessment of organs, interview of the family, and donor 
maintenance care prior to organ recovery.14,15 Usually, after being con-
tacted by State Coordination, surgical teams extract kidneys, and place 
them in perfusion solution and melting ice. After release of results 
compatibility testing, the State Coordination determines which are the 
respective recipients and forwards the kidneys to the transplantation 
hospital where recipients are enrolled in the waiting list. Because our 
hospital is not a recovery center (it does not perform surgical removal), 
the kidney is delivered, on average, after 22 hours of CIT.
In most centers where the perfusion machine is used, in general, 
the kidney is placed on a MP in the donors’ operating room and they 
are pumped during the whole cold ischemic time. In contrast, in our 
transplantation center, the kidney is connected to the MP after a long 
period of static cold storage that preceded the arrival of the kidney in 
our institution (Figure 1).
Some experimental studies showed that hybrid perfusion (ie, 
kidneys that remain in CS and that were subsequently placed in the 
MP) evolved with improvement of some hemodynamic parameters 
and better renal function.16-19 The New York City OPO uses a hybrid 
strategy for kidneys allocated from a distant procured donor hospital 
(imported kidneys); these kidneys arrive after a mean CIT of 32 hours 
in preservation solution and ice and are connected to the MP when 
they arrive in New York City.17 However, the employment of machine 
perfusion following static cold storage vs the use of machine perfusion 
throughout the entire preservation period is still a matter of debate 
and recently has been investigated.20
The main objective of our study was to evaluate the impact of MP 
after a long time of CS static perfusion (hybrid perfusion) on DGF rate, 
length of hospital stay after transplant surgery and dialysis duration, 
acute rejection within the first 14 days, and renal function at discharge 
and at 6 months.
As secondary objectives, this study sought to (i) evaluate whether 
MP hemodynamic parameters, as renal resistance and renal flow cor-
relate with the outcomes (DGF, length of hospital stay after transplant 
surgery and dialysis duration, acute rejection within the first 14 days 
and renal function at discharge and at 6 months) and (ii) define the risk 
factors associated with DGF and kidney function at 6 months in this 
population.
2  | MATERIALS AND METHODS
This study was carried out at a single center by the kidney transplan-
tation program of the Hospital Israelita Albert Einstein in São Paulo, 
Brazil. We used a prospective cohort approach and included patients 
who underwent deceased donor kidney transplantation and that the 
preservation method used was kidney perfusion machine after a long 
period of static cold storage, which in this study is called hybrid per-
fusion (HP); a historic control group consisted of renal transplant re-
cipients of organs from deceased donors exclusively preserved using 
a static approach (control group; CS).
Inclusion criteria for the HP group were transplantations done be-
tween February 2013 (when the hybrid strategy began in our institu-
tion) and July 2014. Donors and recipients were all older than 18. After 
a period of cold storage, donor kidneys were connected to MP in our 
center. Exclusion criteria for this group were as follows: participation 
in another trial; kidneys which had been placed on MP in the donors’ 
operating room before the arrival at our center, early graft loss due to 
surgical causes, and violation of immunosuppression routines. During 
the study period, we performed 67 kidney transplantations with or-
gans from deceased donors; of these, seven patients were excluded 
because their kidneys were connected in perfusion machine after the 
extraction, before the arrival at our center, one because of violation of 
the immunosuppression routine, one because the patient was younger 
than 18 years old, and two patients had an early graft loss due to tech-
nical renal allograft thrombosis. Therefore, 54 patients were included 
in the HP group.
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The historic control group included 101 deceased donor renal 
transplant patients from November 2008 and May 2012, whose allo-
cated kidneys were submitted to the CS preservation method. Patients 
who were older than 18 years underwent the procedure in the same 
institution with the same medical team, and received the same clinical 
and surgical care and immunosuppression protocol.
This study was approved by the ethical and research committee at 
our institution. The need for consent was waived because the preser-
vation method was selected before the transplantation and is a step 
in the routine care delivery to all transplants from deceased donors. 
Identifier: 36993814.9.0000.0071.
2.1 | Logistics and use of machine perfusion
The kidney arrives at our center after a mean static CIT of 22 hours, 
preserved in Euro- Collins solution. The transplantation surgical team 
conducts the back table and then connects the kidney to the perfu-
sion machine (LifePort Kidney Transporter [Organ Recovery Systems, 
Chicago, IL USA]), which is monitored by the nursing team. According 
to our institution’s protocol, the kidney remains in the perfusion ma-
chine for at least 6 hours. Based on the experience of New York City 
OPO,17 the perfusion solution KPS- 1 is used in the perfusion machine, 
and as initial parameter, a 30- mm Hg systolic pressure of perfusion 
is maintained at a temperature about 1- 8°. While the kidney is in the 
perfusion machine, we monitored and recorded the flow and intra- 
renal resistance in real time at 0 hours, 1 hour, 6 hours, and when the 
kidney was disconnected from the machine (final).
2.2 | Immunosuppression protocol
All patients in both groups received induction with one intraoperative 
dose of thymoglobulin, 1.5 mg/kg body weight, followed by sequential 
doses of 1.0 mg/kg body weight according to CD3 cell counts, as pre-
viously reported.21 The maintenance immunosuppression regimen was 
composed of tacrolimus (0.1 mg/kg body weight every 12 hours), pred-
nisone (0.5 mg/kg body weight), and mycophenolate sodium (720 mg 
every 12 hours). Calcineurin inhibitor therapy was initiated after an-
tithymocyte globulin suspension. All patients received prophylaxis with 
trimethoprim- sulfamethoxazole up to 6 months after transplantation. 
There was no other protocol change between both groups in this study.
2.3 | Data collection
Data were collected retrospectively from electronic medical records 
for the control group (CS) and in real time for the HP group using a 
specific form created to monitor these patients.
2.4 | Analyzed outcomes
Outcomes analyzed were delayed graft function (defined as the need 
for dialysis in the first week after transplantation), primary nonfunc-
tion, duration of DGF in days, acute rejection within the first 14 days, 
length of hospital stay, renal function (measured by creatinine and by 
glomerular filtration rate [GFR] as estimated by the Modification of 
Diet in Renal Disease equation) at discharge and at 6 months.
2.5 | Data analysis
Numerical variables with normal distribution by the Shapiro- Wilk test 
were described as means and standard deviations; non- normally dis-
tributed variables were described as medians and interquartile ranges 
and as minimal and maximal values.
Groups were compared in relation to observed variables. For nor-
mally distributed variables, the comparison was performed using the 
Student t- test; data not normally distributed were compared in groups 
using the Mann- Whitney U test. Categorical variables were compared 
by chi- squared test or Fisher’s exact test depending on the number of 
individuals in each class.
We verified the association between final renal flow and final renal 
resistance within the perfusion circuit of machine perfusion with sev-
eral variables using linear regression models and logistic regression.
Subanalyses were performed to evaluate the benefit of the use of 
the machine on outcomes (DGF, time of DFG, renal function, length of 
hospital stay) in some subgroups of patients according to some charac-
teristics of donors considered to be present as high risk for DGF, such 
as	the	donor	age	older	than	≥50	years	and	according	to	the	expanded	
criteria.
Variables previously selected by the researcher were tested, in-
cluding risk factors for DGF and GFR at 6 months in the univariate 
analysis. Only variables with P value lower than .20 in a univari-
ate analysis were considered for multivariate analysis. Selection for 
the multivariate model was carried out using the stepwise method 
and as selection criterion of variables of AIC along with the resi-
due analysis, always controlled by static ischemia time. Results for 
DGF were obtained using logistic regression models. Results for es-
timated GFR (eGFR) were achieved using Gaussian linear regression 
models.
Relationships between pumping time, final renal resistance, and 
DGF were investigated using the Mann- Whitney U test. The associa-
tion between pumping time and renal function was determined using 
the Spearman correlation coefficient.
Results are presented as estimated coefficients, 95% confidence 
intervals, and P values. Level of significance adopted was 5%. Analyses 
were performed using the R package (R Core Team, 2013).
3  | RESULTS
3.1 | Clinical and demographic characteristics of 
donors and recipients, transplant characteristics, and 
hemodynamic parameters of machine perfusion
Clinical and demographic characteristics of recipients and donors, 
transplant characteristics, and hemodynamic parameters of MP are 
described in Table 1. Recipients in the HP group were younger than 
those in the CS group (44.5 years vs 55 years; P = .006). No significant 
differences were observed for the other demographic characteristics. 
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Among transplant variables, we observed that the HP group had a 
shorter duration of static cold storage time (20 vs 22 hours; P = .017) 
and longer duration of total CIT (31.5 vs 22 hours; P = .017). The mean 
pumping time was 11 hours (25% and 75% interquartile range, 9.25 and 
13.75 hours). The pumping time was approximately half the time of CS 
(median, 20 hours; 25% and 75% interquartile range, 17 and 22 hours). 
No other significant differences between the two groups were seen.
3.2 | Comparison of outcomes between the cold 
storage and hybrid perfusion groups
None of the groups presented primary nonfunction. The use of the HP 
significantly reduced the incidence of DGF: 79.2% in the CS group and 
61.1% in the HP group (P = .022). The duration of dialysis after trans-
plantation was reduced from 11 to 5 days (P < .001), and the length 





(n = 54) P value
Recipient characteristics
Median recipient age (years) 55.00 [45.00, 60.00] 44.50 [37.25, 54.75] .006
Recipient gender
Male 67 (66.3%) 30 (55.6%) .223
Median duration of pretransplantation dialysis (months) 54.00 [30.00, 87.00] 35.50 [13.00, 90.25] .057
Cause of chronic renal disease
Hypertension 20 (19.8%) 4 (7.4%) .053
Diabetes 18 (17.8%) 8 (14.8%)
GN 9 (8.9%) 8 (14.8%)
Polycystic disease 16 (15.8%) 4 (7.4%)
Other 38 (37.6%) 30 (55.6%)
Median PRA (%) 0.00 [0.00, 0.50] 0.00 [0.00, 0.00] .805
Median HLA mismatches 3.00 [2.00, 4.00] 3.00 [2.00, 3.00] .997
Donor characteristics
Donor age (years) 43.00 [29.00, 52.00] 42.50 [27.25, 50.75] .492
Donor gender
Male 56 (55.4%) 33 (61.1%) .609
Donor hypertension
Yes 35 (35.0%) 15 (28.3%) .47
Donor cause of death – CVA
Yes 53 (52.5%) 23 (42.6%) .312
Donor terminal creatinine (mg/dL) 1.32 [0.99,1.97] 1.30 [0.88, 1.83] .604
Expanded criteria donor
Yes 29 (28.7%) 10 (18.5%) .18
Ischemic times
Median static cold ischemic time (hours) 22.00 [20.00, 23.00] 20.00 [17.00, 22.00] .017
Median pumping perfusion time (hours) - 11.00 (9.25, 13.75) - 
Median total ischemic time (static + pumping) (hours) 22.00 [20.00, 23.00] 31.50 [28.00, 34.00] <.001
Hemodynamic machine parameters
Median initial flow (mL/min) - 55.00 [38.25. 69.00] - 
Mean 1 h flow (mL/min) - 94.78 (31.24) - 
Mean 6 h flow (mL/min) - 98.15 (28.27) - 
Mean final flow (mL/min) - 102.91 (30.37) - 
Median initial resistance (mm Hg/mL/min) - 0.46 [0.39, 0.66] - 
Median 1 h resistance (mm Hg/mL/min) - 0.26 [0.22,0.32] - 
Median 6 h resistance (mm Hg/mL/min) - 0.23 [0.21, 0.30] - 
Median final resistance (mm Hg/mL/min) - 0.23 [0.20, 0.30] - 
Median values are reported with interquartile range.
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of hospital stay decreased from 18 to 13 days (P < .001) in HP. Acute 
rejection rate within the first 14 days, renal function at discharge and 
at 6 months did not significantly differ between groups (Table 2).
3.3 | Hemodynamic parameters in hybrid perfusion  
group
The two hemodynamic parameters evaluated were intrarenal flow (F) 
and intrarenal resistance (R), described in Table 1. F increased from 55 
to 102.9 mL/min, whereas R decreased from 0.46 to 0.23 while the 
kidney remained in the MP. For both parameters, the variation was 
greater during the first hour of placement in the MP (Table 1).
Considering the association between the final renal flow and out-
comes, for each unit increase in the final renal flow, we expect a 0.210 mL/
min increase in the discharge creatinine clearance value (P = .021) and 
0.237 mL/min in the creatinine clearance value in 6 months (P = .035).
We also analyzed the association between the final resistance 
and outcomes. For each increase of 0.1 units in the final renal resis-
tance, we expect an increase of 1.5 days in DGF (P = .009). For each 
increase of 0.1 unit increase in final resistance, we expect a decrease 
of 4.101 mL/min in the discharge creatinine clearance value (P = .022) 
and a decrease of 6.307 mL/min in the clearance of creatinine value of 
6 months after transplantation (P = .013).
3.4 | Subanalyses of risk groups
In	the	subgroup	of	donors	aged	≥50	years,	patients	in	the	HP	group	
(n = 16) had a shorter hospital stay (10.50 vs 22 days; P = .006) and 
shorter dialysis duration (4.00 vs 12.50 days; P = .023) than CS group 
(n = 35). In this subgroup, the HP did not reduce the DGF rate.
In the subgroup analysis consisting only of expanded criteria do-
nors, 10 patients were included in HP group vs 29 patients in CS group, 
and no difference in outcomes was seen when CS and HP groups were 
compared.
3.5 | Factors associated with delayed graft function
In univariate analysis, risk variables statistically significant associ-
ated with DGF were donor age (OR, 1.04; P = .002), CIT (OR, 1.14; 
P = .011), cerebrovascular accident as the cause of the donor death 
(OR, 2.12; P = .045), donor with hypertension (OR, 2.59; P = .030), and 
expanded criteria donor (OR, 3.19; P = .026). The pumping time (OR, 
0.93; P = .013) and belonging to the HP group (OR, 0.41; P = .017) 
decreased the DGF risk (Table 3).
In multivariate analysis, adjusted for static cold ischemic time, inde-
pendent risk factors for DGF were donor age (OR, 1.04; P = .005) and 
belonging to the HP group (OR, 0.46; P = .051). Therefore, for each year 
of increase in donor age, there was a 4% increase in the chance of DGF. 
In addition, belonging to the HP group decreased the chance of DGF 
by 54% after adjustment for variables included in this model (Table 3).
3.6 | Factors associated with glomerular filtration 
rate at 6 months
In the univariate analysis, risk factors significantly associated with 
worse renal function at 6 months were expanded criteria donor, 
donor	age	≥50	years,	cerebrovascular	accident	as	the	cause	of	donor	
death, donor with hypertension, recipient’s age, and DGF (Table 4). In 
the multivariate analysis, adjusting for static cold ischemic time, both 
cerebrovascular accident as the cause of donor death (P < .001) and 
donor	age	≥50	years	(P = .027) were variables of risk for worse renal 
function at 6 months (Table 4).
4  | DISCUSSION
This study showed that use of MP after a period of cold static is-
chemia, in the HP group, reduced the DGF rate compared with the 




n = 54 P value
Recipient outcomes
Primary nonfunction 0 0 - 
Delayed graft function
No 21 (20.8%) 21 (38.9%) .022
Yes 80 (79.2%) 33 (61.1%)
Length of DGF 11.00 [7.00, 15.00] 5.00 [1.00, 10.00] <.001
Acute rejection within 14 d after transplantation
No 90 (89.1%) 48 (88.9%) .578
Yes 11 (10.9%) 6 (11.1%)
Median length of hospital stay 
(days)
18.00 [12.00, 24.00] 13.00 [8.25, 16.75] <.001
Median discharge eGFR (mL/
min)
26.08 [18.26, 36.19] 32.65 [18.52, 45.95] .254
Median eGFR at 6 mo (mL/min) 57.41 [44.60, 72.76] 55.00 [43.00, 65.60] .256
Median values are reported with interquartile range.
TABLE  2 Comparison of outcomes 
between cold storage (CS) and hybrid 
perfusion (HP) groups
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analysis the use of the HP reduced the DGF risk (OR, 0.46; CI, 0.21- 
1.01; P = .051). The duration of dialysis and hospitalization was also 
lower in the HP group (median: 11 vs 5 days [P < .001] and 18 vs 
13 days [P < .001]), respectively. Therefore, the HP group presented 
faster recovery of graft function, such as reported by other authors 
who compared MP and CS preservation methods.8 In a previous 
study, Sandes- Freitas et al categorized patients in quartiles according 
to duration of DGF and they showed that the highest quartile, which 
was named as prolonged DGF (>15 days), had a negative impact on 
graft function, patient and graft survival at 1 year. In addition, the pro-
longed DGF was an independent risk factor to graft loss (OR: 3.876 
P < .001) and death (OR: 3.065 P = .001); therefore, the longer the 
DGF duration, the worse the graft and the patient survivals will be.22 
Considering this, as the HP group in our study reduced the duration 
of DGF from 11 to 5 days, this might be considered an additional ben-
efit of HP strategy, to prevent the damage associated with prolonged 
DGF on graft and patient survivals.
As	transplantations	with	organs	from	donors	aged	≥50	years	and	
transplants from expanded criteria donors are associated with worse 
outcomes after transplantation, such as higher rates of DGF and lower 
graft survival,23 we performed a subanalysis considering only donors 
aged	≥50	years	 and	 expanded	 criteria	 donors.	A	 subanalysis	 includ-
ing only expanded criteria donors showed that the use of HP did not 
improve results after the transplantation. This result differs from find-
ings in other studies showing that MP reduced the DGF rate and im-
proved 1- year graft survival in expanded criteria donors.24,25 On the 
other	hand,	 in	 the	subanalysis	of	donors	aged	≥50	years,	 the	use	of	
the HP did not reduce the DGF rate, but the duration of DGF was 
lower than in the control group, which might have a positive impact in 
long- term results. The lack of benefits with related to the use of MP 
after a long CIT in transplants from expanded criteria donors may be 
due to these kidneys are more susceptible to ischemic injury in gen-
eral, they have lower renal mass, more chronic histologic injuries, and 
lower ability for repair and regeneration.23 However, we must consider 
that these subanalysis involved a small sample of patients. Recently, 
Gallinat et al performed a study where they compared the results of 
expanded criteria donors kidneys from the same donor, one of them 
being preserved in cold storage and the other in perfusion machine 
after a period of cold storage (mean pumping time: 5.5 hours, mean 
cold ischemic time in CS group: 12.1 hours, and mean cold ischemic 
time in MP group: 13.4 hours). The authors observed a lower rate of 
primary nonfunction in HP group (0% vs 9.3%), and they have showed 
that the HP strategy was an independent factor for prevention of DGF 
TABLE  3 Univariate and multivariate analysis: risk factors for 
delayed graft function (DGF)
Variable Estimate OR P value
Univariate analysis
Donor age 0.04 1.04 .002
Cold static ischemic time (hours) 0.13 1.14 .011
Pumping time (hours) −0.07 0.93 .013
HP group (yes) −0.89 0.41 .017
Expanded criteria donor (yes) 1.16 3.19 .026
Donor hypertension (yes) 0.95 2.59 .030
Cause of donor death—CVA (yes) 0.75 2.12 .045




0.10 1.10 1.00 1.22 .053
Donor age 
(years)
0.04 1.04 1.01 1.07 .005
HP group (yes) −0.77 0.46 0.21 1.01 .051





Expanded criteria donor (yes) −17.85 −25.91 −9.78 .0001
Donor	age	≥50	y −18.45 −25.72 −11.19 .0001
Donor CVA (yes) −11.33 −18.58 −4.08 .002
Donor hypertension (yes) −11.49 −19.28 −3.71 .004
Recipient age −0.30 −0.58 −0.02 .035





Cold static ischemic time (hours) −0.76 −1.66 0.13 .097
Donor CVA (yes) −7.85 −14.79 −0.91 <.001
Donor	age	≥50	y −15.91 −23.27 −8.56 .027
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(OR:0. 28, P = .041), as our study has also observed. The DGF rate was 
lower in HP group (20.9% vs 11.6%), and graft and patient survivals at 
1 year were slightly better in HP group, however, without statistical 
significance. The authors believe the pulsatile stimulation of the reno-
vasculature is an important reason for these results. It might preserve 
the vascular endothelium and its phenotype, preventing transcription 
of inflammatory and vasoconstrictors factors.20
Although the total CIT was significantly longer in the HP group, 22 
vs 31.5 hours (P < .001), with 11 hours on perfusion machine, no harm 
to the graft was seen with use of the HP. Our protocol for the perfu-
sion machine use requires a minimum of 6 hours, but the mean time in 
this study was 11 hours due to logistic reasons, that is, we were able 
to wait for patients who lived in distant regions and to avoid transplant 
surgery at dawn hours.
This result corroborates with that of a previous study show-
ing that use of MP may extend the total CIT without injuring the 
graft.20,24,26-28 When we evaluated the effect of HP on DGF in a uni-
variate analysis, pumping time had a protective effect on DGF, that 
is, for each 1- hour increase in the pumping time, the risk of DGF 
decreased 7% (OR, 0.93; P = .013), data not shown. Of importance, 
there was no difference among both groups between total doses of 
thymoglobulin, day of initiation of tacrolimus, and its levels at 15, 
30, 90, and 180 days post- transplantation (data not shown). In ad-
dition, a study using data from the Scientific Registry of Transplant 
Recipients (SRTR) comparing these two perfusion strategies (CS vs 
MP) reported that the longer the pumping time, the lower the DGF 
risk is.24 We believe that the effect of pumping time might be associ-
ated with an improvement of hemodynamic parameters, reduction of 
oxidative and metabolic stress, and consequently vascular injury.29 In 
addition, MP probably reduces the graft susceptibility to warm isch-
emic time and reperfusion injuries related in the graft.18 In addition, 
Gallinat et al30 have also showed in experimental porcine model that 
MP may reduce the damage to the endothelial cell and preserve the 
parenchymal integrity.
Considering hemodynamic parameters of the machine, after an 
hour of machine perfusion use, an important decrease in vascular 
renal resistance was seen (from 0.46 to 0.26 mm Hg/mL/min) and a 
significant increase in renal flow occurred (from 55 to 99.8 mL/min); 
these changes are similar to those reported in a previous study.27 
We observed no significant differences in hemodynamic parameters 
measured in subsequent hours. Variations in flow and vascular renal 
resistance can be directly associated with hemodynamic effect of MP 
related to renal vasodilatation and the capability of this graft to re-
spond to this effect. Grafts with vascular changes mainly associated 
with aging and vascular disease probably have a lower response to 
the hemodynamic effect of machine perfusion. In our study, both final 
renal flows as the final vascular renal resistance were associated with 
renal function at discharge and at 6 months, directly and inversely, 
respectively. However, in multivariate analysis, these two variables 
were not associated with DGF or GFR risk at 6 months. However, this 
lack of association is different from the findings in other studies that 
showed final vascular renal resistance as a risk factor for DGF and graft 
loss after 1 year.31 Either DGF or eGFR are multifactorial dependent; 
therefore, in our models others variables were more important as risk 
factors for DGF and eGFR than the hemodynamic parameters.
In multivariate analysis, belonging to HP group did not impact the 
renal function at 6 months. In our study, renal function at 6 months 
was associated only with donor age and the presence of cardiovas-
cular disease. Of importance, there was no difference among both 
groups, HP vs CS, in renal function (data not shown). Other studies 
also found no difference in short- and long- term renal function after 
transplantation between the two preservation strategies.8,10,32 In our 
model, the variables related to the quality of the donor, as age and 
presence of cardiovascular disease, were more determinants for renal 
function. The preservation and ischemic injuries in the kidneys of older 
donors may be less responsive to the benefits of HP. However, during 
the first 6 months after transplantation, a variety of injuries still occur-
ring in the graft, such as those related to higher doses of immunosu-
pressors, immunologic, opportunistic infections, can mask the benefit 
of machine perfusion in this period.
Our results should be interpreted with caution because we used 
a small sample of patients in HP group, we did not use a randomized 
approach, and we retrospectively analyzed the control group. In ad-
dition, other factors that cannot be disregarded are the concomitant 
use of MP with a perfusion solution, which is well recognized as more 
efficient than Euro Collins, such as KPS- 1, the control group used 
Euro Collins solution for preservation, which is associated with higher 
DGF rate.31-33 The Euro Collins solution is used even less in US and 
European centers, but it is still commonly used in Brazil because of its 
lower cost.34 The use of this solution is considered another reason that 
may contribute to our high rates of DGF.
In conclusion, our study showed that it is possible to use machine 
perfusion after a long period of static cold ischemia to reduce the risk 
and rate of DGF and the duration of DGF thereby enabling faster re-
covery of graft function, avoiding the damage related to DGF and pro-
longed DGF. The observed reduction of DGF with machine perfusion 
did not occur in donors over 50 years old.
In addition, using the support of hemodynamic parameters, it is 
possible to predict how graft function will evolve. Because of the rules 
and current conditions for the organ procurement system in Brazil, 
it is not possible to reduce the time of static cold storage ischemia; 
therefore, the use of a machine after long CS can be an alternative to 
improve graft quality and transplantation results. A randomized study 
comparing the two strategies and including a large sample of patients 
can confirm these results and long- term effects. A cost- effectiveness 
analysis should be also considered to help the federal government 
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